Beth Sandy, MSN, CRNP, FAPO

Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Authored Items

Patient-Reported Outcomes Highlight Favorable Tolerability of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial
By Beth Sandy, MSN, CRNP, FAPO
American Society of Clinical Oncology (ASCO)
ASCO 2025 - Non-Small Cell Lung Cancer
Patient-reported outcomes from the Beamion LUNG-1 trial showed sustained improvements in physical functioning and symptom burden, with low side effect severity, supporting zongertinib’s potential in advanced NSCLC. Read More ›
Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial
By Beth Sandy, MSN, CRNP, FAPO
American Society of Clinical Oncology (ASCO)
ASCO 2025 - Non-Small Cell Lung Cancer
The SOHO-01 trial highlights the manageable safety and promising efficacy of sevabertinib (BAY 2927088) in patients with pretreated or untreated HER2-mutant NSCLC. Read More ›


© Amplity, Inc. All Rights Reserved. Privacy Policy